**P64** IMPACT OF SUSPECTED LIVER DISEASE ON METHOTREXATE PRESCRIBING IN PATIENTS WITH PSORIASIS

1Anthony Pratt*, 1Lucy Turner, 1John Hutchinson, 1Dawn Orange, 1Laura Mahes, 1Charlie Millson, 1York Teaching Hospital NHS Foundation Trust, UK; 2The Mid Yorkshire Hospitals NHS Trust, UK

Introduction Methotrexate is a first line treatment for psoriasis. Routine monitoring includes liver function tests (LFTs) and type 3 procollagen peptide (P3NP). Methotrexate is known to cause alanine aminotransferase elevations however significant liver disease is rare, even in long term use. Where methotrexate is ineffective, contra-indicated or causes adverse drug reactions (ADRs), ustekinumab can be considered but at an additional cost of up to £8,550 per patient per annum. We investigated whether methotrexate was being under-prescribed due to suspected liver disease and whether these patients were referred to hepatology as advised by national guidance.

Method Electronic clinic letters were examined for all patients prescribed ustekinumab by the dermatology team at York Teaching Hospital Trust. Reasons for not prescribing, or stopping methotrexate were analysed. Where these included suspected liver disease, we identified risk factors for liver disease and metabolic syndrome and looked for evidence of referral of these patients to our hepatology department.

Results 14/146 (9.6%) patients were not prescribed methotrexate due to suspected liver disease. This was mostly due to increased LFTs and/or history of alcohol excess (>14 units/week) at baseline. Two (1.4%) further patients were thought to have cirrhosis. 25/146 (17%) patients were commenced on methotrexate but discontinued due to increases in LFTs and/or P3NP. The most common risk factors for liver disease and metabolic syndrome were body mass index >25 kg/m², alcohol excess and hypertension. 13/41 (32%) 40/41 (98%) patients had at least one risk factor for liver disease or metabolic syndrome. Only 12/41 (29%) patients were referred to hepatology, six patients underwent transient elastography (Fibroscan®) where results were all less than 7kPa ruling out significant liver disease. Only two patients with cirrhosis had an absolute contra-indication to methotrexate. The remaining 39/41 (95%) were under-prescribed methotrexate due to suspected liver disease, resulting in escalation of treatment and additional total drug costs of up to £333,450 per annum.

Conclusion Suspected liver disease limited the use of methotrexate in 28% of patients with psoriasis, ultimately leading to prescribing ustekinumab at a cost of up to £333,450 more per annum compared to methotrexate. More research is needed to determine if methotrexate could still be used in this population with appropriate hepatology monitoring.

**P65** ELEVATED NUMBERS AND SIZE OF AGGREGATES OF IMMUNE CELLS PROTECTS AGAINST LIVER CANCER PROGRESSION

1Sam Wanders Cottingham*, 1Joao Mauricio-Muir, 1Misti Vanette McCain, 1Robyn Watson, 1Catriona Evans, 2Caroline Wilson, 1Alastair Burt, 2Derek Mann, 1Ruchi Shukla, 1Helen Reeves. 1Newcastle University Translational and Research Institute, Newcastle upon Tyne, UK; 2Newcastle University Biosciences Institute, Newcastle upon Tyne, UK; 3Newcastle upon Tyne NHS Hospitals Foundation Trust, Newcastle upon Tyne, UK

Background Deaths from hepatocellular carcinoma (HCC) are rising. HCC typically develops in the setting of inflammation and chronic liver disease, where the immune environment can either promote or suppress cancer growth. Immune cells infiltrate within HCC are also suspected to play a key role in determining patient responses to treatments, but this is poorly understood. As the therapeutic options for patients with advanced HCC are changing, with a small minority (<15%) responding dramatically to immune checkpoint (PD-1/PD-L1) inhibition, the need to understand the complexities of the immune environment in liver cancers and develop strategies to improve survival for more patients, is ever more pressing.

Methods Surplus tissues from 58 patients with HCC undergoing diagnostic biopsy, presenting to the Newcastle upon Tyne Hospitals NHS Foundation Trust and recruited to our study, were investigated whether methotrexate was being under-prescribed due to suspected liver disease and whether these patients were referred to hepatology, as advised by national guidance.

Results Immune aggregates were detected in HCC in 28/58 patients. Simple ‘presence’ was not significantly associated with any clinicopathological features. However, higher number of aggregates (n=14) was associated with less advanced TNM stage (p=0.015), longer time to radiological progression (20.9 vs 8.0 months, Kaplan-Meier, p=0.033) and longer survival (34.0 vs 20.9 months, p=0.024) compared to lower or absent cases (n=44). Furthermore, mean aggregate area correlated negatively with tumour size (Spearman’s Rho -0.413, p=0.029). Patients with larger aggregates were more likely to have a maximal tumour diameter <5 cm (13/14 versus 21/44; Chi Square p=0.006). The majority of aggregates (89%) regardless of size had detectable PD-1 expression, which awaits post pandemic characterisation. Patients with larger aggregates were more likely to have high intratumoral CD66b positive neutrophils (8/12 versus 10/37; Chi square p= 0.013).

Conclusion Higher numbers and size of immune aggregates were associated with delayed tumour progression, highlighting the need to further define the tumour immune environment in patients with HCC.

**P66** A PEER LED PARTNERSHIP ACHIEVES WHOLE SUBSTANCE MISUSE SERVICE HCV TESTING AND TREATMENT

1Carrie Richardson, 1Mark Burns*, 1Danny Morris, 2Bearnne Dilks, 2Stephen Ryder, 3Anna Willoughby. 1The Hepatitis C Trust, UK; 2NIHR Nottingham Biomedical Research Centre at Nottingham University Hospitals and the University of Nottingham, Nottingham, UK; 3We Are With You, London, UK

Background People who inject drugs (PWID) living in remote settings across the UK commonly experience levels of isolation with increased difficulty accessing hepatitis C (HCV) testing and treatment. Many individuals may be engaged with substance misuse services (SMS) while experiencing difficulties in navigating pathways and overcoming barriers to accessing health services. Due to the remote patient and limited support in these areas, and isolation, we established a community-led partnership to improve HCV testing and treatment uptake.

Abstracts

10.1136/gutjnl-2020-BASL.74

10.1136/gutjnl-2020-BASL.76

10.1136/gutjnl-2020-BASL.75
secondary care resulting in missed opportunities for HCV treatment.

**Objective** To determine if the introduction of peer support, working collaboratively with clinicians and SMS providers by providing peer-led pro-active engagement, support and education can promote treatment uptake and reduce testing to treatment pathway times to 4 weeks or less.

**Description of intervention** A Peer Support Lead supported by peers with lived experience of HCV, working in partnership with a Clinical Nurse Specialist (CNS) and SMS practitioners coordinated a two-week intensive HCV PCR testing programme targeting service users at a small rural town SMS. An information sharing agreement between services was established, facilitating timelier liaison and responsive peer support. Testing was coordinated alongside routine appointments to ensure delivery to all PWID with the service and aimed to test 121 patients identified as at risk. All those identified as HCV +ve were supported by peers to access treatment, delivered within the SMS community.

**Effectiveness** The model was welcomed by service users who valued reassurance and guidance in getting tested and treated. Of the 18 patients referred, to date 15 have started treatment.

Results from the 121 service-users who were identified as at risk were highly productive. 116 individuals were tested and results demonstrated 35 as antibody + for HCV, 18 PCR + and 15 commenced treatment at the time of writing.

Additionally, SMS Recovery Coordinators demonstrated increased confidence in promoting HCV testing and treatment.

**Conclusion and Next Steps** Objectives were met - in shortening the test to treatment pathway and 83% of service-users identified as HCV + commencing treatment. The successful peer led multi-agency approach has proved replicable and is now being expanded across other locations. The project also has proven effective in promoting a visible message of simplicity and ease of HCV treatment to service-users.

**Disclosure of Interest Statement** The Hepatitis C Trust has received funding via the NHS England elimination agenda and ease of HCV treatment to service-users. Proven effective in promoting a visible message of simplicity being expanded across other locations. The project also has proven effective in promoting a visible message of simplicity and ease of HCV treatment to service-users.

**Abstract P67 Figure 1**

Conclusions Elevated Survivin expression in surgically resected primary liver cancers correlates with adverse clinical features and lower cumulative survival. Applying digital pathological techniques based on whole-slide detection of tumour antigens on archived tissue has the potential to provide useful clinical insights.